Between Scylla and Charybdis: The role of the human immune system in the pathogenesis of hepatitis C

World Journal of Gastroenterology

Volumn 19, Issue 44, 2013, Pages 7852-7866

  Spengler, Ulrich ^a   Nischalke, Hans Dieter ^a   Nattermann, Jacob ^a   Strassburg, Christian P ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Hepatic stellate cells; Hepatitis C; Hepatocytes; Immunoglobulin; Interferon; Natural killer cells; Regulatory T cells; Retinoic acid inducible gene I; Toll like receptors

Indexed keywords

CD56 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 28A; INTERLEUKIN 35; INTERLEUKIN 8; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4; PATTERN RECOGNITION RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; RIBAVIRIN; STAT PROTEIN; TOLL LIKE RECEPTOR 3; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DNA POLYMORPHISM; GENE MUTATION; HEPATITIS C; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; LIVER CIRRHOSIS; LIVER NECROSIS; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; TISSUE INJURY; TREATMENT OUTCOME; VIRUS PATHOGENESIS;

CD4+ T HELPER CELLS; HEPATIC STELLATE CELLS; HEPATITIS C; HEPATOCYTES; IMMUNOGLOBULIN; INTERFERON; NATURAL KILLER CELLS; REGULATORY T CELLS; RETINOIC ACID INDUCIBLE GENE-I; TOLL LIKE RECEPTORS;

ADAPTIVE IMMUNITY; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS ANTIGENS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INTERFERONS; KILLER CELLS, NATURAL; LIVER CIRRHOSIS; LIVER NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84888602283     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i44.7852     Document Type: Article

References (185)

1. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Göbel U, Capka E, Wiegand J, Schiefke I, Güthoff W, Grüngreiff K, König I, Spengler U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-1592, 1592.e1 [PMID: 20637200]
2. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-88 [PMID: 12851873 DOI: 10.1016/S0016-5085(03)00668-1]
3. Brillanti S, Foli M, Gaiani S, Masci C, Miglioli M, Barbara L. Persistent hepatitis C viraemia without liver disease. Lancet 1993; 341: 464-465 [PMID: 8094491 DOI: 10.1016/0140-6736(93)90210-8]
4. Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, Ruol A. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697-698 [PMID: 1355801 DOI: 10.1016/0140-6736(92)92234-7]
5. Farci P, Alter HJ, Shimoda A, Govindarajan S, Cheung LC, Melpolder JC, Sacher RA, Shih JW, Purcell RH. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996; 335: 631-634 [PMID: 8687517 DOI: 10.1056/NEJM199608293350904]
6. André P, Perlemuter G, Budkowska A, Bréchot C, Lotteau V. Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis 2005; 25: 93-104 [PMID: 15732001 DOI: 10.1055/s-2005-864785]
7. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327: 291-295 [PMID: 20075244 DOI: 10.1126/science.1183021]
8. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int 2009; 29 Suppl 1: 89-99 [PMID:19207971DOI:10.1111/j.1478-3231.2008.01927.x]
9. McAllister CS, Samuel CE. The RNA-activated proteinkinase enhances the induction of interferon-beta and apoptosis mediated by cytoplasmic RNA sensors. J Biol Chem 2009; 284: 1644-1651 [PMID: 19028691 DOI: 10.1074/jbc. M807888200]
10. Uzri D, Gehrke L. Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J Virol 2009; 83: 4174-4184 [PMID: 19224987 DOI:10.1128/JVI.02449-08]
11. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M. Innateimmunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008; 454: 523-527 [PMID: 18548002 DOI: 10.1038/nature07106]
12. Loo YM, Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011; 34: 680-692 [PMID: 21616437 DOI: 10.1016/j.immuni.2011.05.003]
13. Li K, Li NL, Wei D, Pfeffer SR, Fan M, Pfeffer LM. Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Tolllike receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 2012; 55: 666-675 [PMID: 22030901 DOI: 10.1002/hep.24763]
14. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009; 227: 75-86 [PMID:19120477DOI:10.1111/j.1600-065X.2008.00737.x]
15. Shimoike T, McKenna SA, Lindhout DA, Puglisi JD. Translational insensitivity to potent activation of PKR by HCV IRES RNA. Antiviral Res 2009; 83: 228-237 [PMID: 19467267 DOI: 10.1016/j.antiviral.2009.05.004]
16. Arnaud N, Dabo S, Akazawa D, Fukasawa M, ShinkaiOuchi F, Hugon J, Wakita T, Meurs EF. Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog 2011; 7: e1002289 [PMID: 22022264 DOI: 10.1371/ journal.ppat.1002289]
17. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M, Fujita T, Saito T, Lee WM, Hagedorn CH, Lau DT, Weinman SA, Lemon SM, Gale M. Viral and therapeutic control of IFN beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 2006; 103: 6001-6006 [PMID: 16585524 DOI: 10.1073/pnas.0601523103]
18. Baril M, Racine ME, Penin F, Lamarre D. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J Virol 2009; 83: 1299-1311 [PMID: 19036819 DOI: 10.1128/JVI.01659-08]
19. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 2005; 102: 17717-17722 [PMID: 16301520 DOI: 10.1073/pnas.0508531102]
20. Foy E, Li K, Sumpter R, Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA 2005; 102: 2986-2991 [PMID: 15710892 DOI: 10.1073/ pnas.0408707102]
21. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 1167-1172 [PMID: 16177806 DOI: 10.1038/nature04193]
22. Yang Y, Liang Y, Qu L, Chen Z, Yi M, Li K, Lemon SM. Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc Natl Acad Sci USA 2007; 104: 7253-7258 [PMID: 17438296 DOI: 10.1073/ pnas.0611506104]
23. Bellecave P, Sarasin-Filipowicz M, Donzé O, Kennel A, Gouttenoire J, Meylan E, Terracciano L, Tschopp J, Sarrazin C, Berg T, Moradpour D, Heim MH. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 2010; 51: 1127-1136 [PMID: 20044805 DOI: 10.1002/hep.23426]
24. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M, Lemon SM. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Tolllike receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005; 102: 2992-2997 [PMID: 15710891 DOI: 10.1073/ pnas.0408824102]
25. Wang N, Liang Y, Devaraj S, Wang J, Lemon SM, Li K. Tolllike receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J Virol 2009; 83: 9824-9834 [PMID: 19625408 DOI: 10.1128/JVI.01125-09]
26. Zhang Z, Kim T, Bao M, Facchinetti V, Jung SY, Ghaffari AA, Qin J, Cheng G, Liu YJ. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity 2011; 34: 866-878 [PMID: 21703541 DOI: 10.1016/j.immuni.2011.03.027]
27. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-110 [PMID: 10390359 DOI:10.1126/science.285.5424.107]
28. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-227 [PMID: 9143277 DOI: 10.1006/viro.1997.8493]
29. Noguchi T, Satoh S, Noshi T, Hatada E, Fukuda R, Kawai A, Ikeda S, Hijikata M, Shimotohno K. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells. Microbiol Immunol 2001; 45: 829-840 [PMID: 11838900]
30. Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 2007; 82: 479-487 [PMID: 17595379 DOI: 10.1189/jlb.0207128]
31. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004; 127: 1513-1524 [PMID: 15521019 DOI: 10.1053/j.gastro.2004.08.067]
32. Coenen M, Nischalke HD, Krämer B, Langhans B, Glässner A, Schulte D, Körner C, Sauerbruch T, Nattermann J, Spengler U. Hepatitis C virus core protein induces fibrogenic actions of hepatic stellate cells via toll-like receptor 2. Lab Invest 2011; 91: 1375-1382 [PMID: 21537327 DOI: 10.1038/labinvest.2011.78]
33. Nischalke HD, Berger C, Luda C, Müller T, Berg T, Coenen M, Krämer B, Körner C, Trebicka J, Grünhage F, Lammert F, Nattermann J, Sauerbruch T, Spengler U. The CXCL1 rs4074 A allele is associated with enhanced CXCL1 responses to TLR2 ligands and predisposes to cirrhosis in HCV genotype 1-infected Caucasian patients. J Hepatol 2012; 56: 758-764 [PMID: 22173151 DOI: 10.1016/j.jhep.2011.10.019]
34. Nischalke HD, Coenen M, Berger C, Aldenhoff K, Müller T, Berg T, Krämer B, Körner C, Odenthal M, Schulze F, Grünhage F, Nattermann J, Sauerbruch T, Spengler U. The tolllike receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer 2012; 130: 1470-1475 [PMID: 21500195 DOI: 10.1002/ijc.26143]
35. Feldmann G, Nischalke HD, Nattermann J, Banas B, Berg T, Teschendorf C, Schmiegel W, Dührsen U, Halangk J, Iwan A, Sauerbruch T, Caselmann WH, Spengler U. Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 4491-4498 [PMID: 16899594 DOI: 0.1158/1078-0432.CCR-06-0154]
36. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77 [PMID: 12483210 DOI: 10.1038/ni875]
37. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 2004; 76: 314-321 [PMID: 15123776 DOI: 10.1189/jlb.0204117]
38. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFNlike response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81: 7749-7758 [PMID: 17507495 DOI: 10.1128/JVI.02438-06]
39. Darnell JE. STATs and gene regulation. Science 1997; 277: 1630-1635 [PMID: 9287210 DOI: 10.1126/science.277.5332.1630]
40. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421 [PMID: 8197455 DOI: 10.1126/science.8197455]
41. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 2002; 277: 9976-9981 [PMID: 11788588 DOI: 10.1074/jbc.M109078200]
42. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001; 19: 378-387 [PMID: 11553846 DOI: 10.1634/stemcells.19-5-378]
43. Malakhov MP, Kim KI, Malakhova OA, Jacobs BS, Borden EC, Zhang DE. High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem 2003; 278: 16608-16613 [PMID: 12582176 DOI: 10.1074/jbc.M208435200]
44. Liu LQ, Ilaria R, Kingsley PD, Iwama A, van Etten RA, Palis J, Zhang DE. A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation. Mol Cell Biol 1999; 19: 3029-3038 [PMID: 10082570]
45. Skaug B, Chen ZJ. Emerging role of ISG15 in antiviral immunity. Cell 2010; 143: 187-190 [PMID: 20946978 DOI:10.1016/j.cell.2010.09.033]
46. Chen L, Li S, McGilvray I. The ISG15/USP18 ubiquitin-like pathway (ISGylation system) in hepatitis C virus infection and resistance to interferon therapy. Int J Biochem Cell Biol 2011; 43: 1427-1431 [PMID: 21704181 DOI: 10.1016/ j.biocel.2011.06.006]
47. Zhang D, Zhang DE. Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res 2011; 31: 119-130 [PMID: 21190487 DOI: 10.1089/jir.2010.0110]
48. Malakhova OA, Kim KI, Luo JK, Zou W, Kumar KG, Fuchs SY, Shuai K, Zhang DE. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 2006; 25: 2358-2367 [PMID: 16710296 DOI:10.1038/sj.emboj.7601149]
49. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ, Zhang DE, Heim MH. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 2009; 29: 4841-4851 [PMID: 19564419 DOI: 10.1128/ MCB.00224-09]
50. Makowska Z, Duong FH, Trincucci G, Tough DF, Heim MH. Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo. Hepatology 2011; 53: 1154-1163 [PMID: 21480323 DOI:10.1002/hep.24189]
51. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault MP, Boyer N, Martinot-Peignoux M, Valla D, Vidaud M, Marcellin P. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57: 516-524 [PMID: 17895355 DOI: 10.1136/ gut.2007.128611]
52. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, Heathcote J, Edwards AM, McGilvray ID. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 1437-1444 [PMID: 15887125 DOI: 10.1053/ j.gastro.2005.01.059]
53. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, Papassotiropoulos A, Roth V, Heim MH. Interferoninduced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-1031 [PMID: 21111740 DOI:10.1053/j.gastro.2010.11.039]
54. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548-1563 [PMID: 17929300 DOI: 10.1002/hep.21853]
55. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-7039 [PMID: 18467494 DOI:10.1073/pnas.0707882105]
56. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 1999; 73: 8469-8475 [PMID: 10482599]
57. Blindenbacher A, Duong FH, Hunziker L, Stutvoet ST, Wang X, Terracciano L, Moradpour D, Blum HE, Alonzi T, Tripodi M, La Monica N, Heim MH. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 2003; 124: 1465-1475 [PMID: 12730885 DOI: 10.1016/S0016-5085(03)00290-7]
58. Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 2004; 126: 263-277 [PMID: 14699505 DOI: 10.1053/ j.gastro.2003.10.076]
59. Zhu H, Zhao H, Collins CD, Eckenrode SE, Run Q, McIndoe RA, Crawford JM, Nelson DR, She JX, Liu C. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology 2003; 37: 1180-1188 [PMID: 12717400 DOI: 10.1053/jhep.2003.50184]
60. Larrea E, Aldabe R, Molano E, Fernandez-Rodriguez CM, Ametzazurra A, Civeira MP, Prieto J. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies. Gut 2006; 55: 1188-1196 [PMID: 16120756 DOI: 10.1136/gut.2005.070060]
61. Hosui A, Takehara T, Ohkawa K, Kanazawa Y, Tatsumi T, Yamaguchi S, Sakamori R, Hiramatsu N, Kanto T, Hayashi N. Suppressive effect on hepatocyte differentiation of hepatitis C virus core protein. Biochem Biophys Res Commun 2006; 346: 1125-1130 [PMID: 16806084 DOI: 10.1016/ j.bbrc.2006.05.114]
62. Zhu H, Nelson DR, Crawford JM, Liu C. Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance. J Interferon Cytokine Res 2005; 25: 528-539 [PMID: 16181053 DOI: 10.1089/jir.2005.25.528]
63. Garaigorta U, Chisari FV. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 2009; 6: 513-522 [PMID: 20006840 DOI: 10.1016/j.chom.2009.11.004]
64. Dill MT, Makowska Z, Duong FH, Merkofer F, Filipowicz M, Baumert TF, Tornillo L, Terracciano L, Heim MH. Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology 2012; 143: 777-786.e1-6 [PMID: 22677194]
65. Chen L, Borozan I, Sun J, Guindi M, Fischer S, Feld J, Anand N, Heathcote J, Edwards AM, McGilvray ID. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 2010; 138: 1123-1133.e1-3 [PMID: 19900446]
66. McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer S, Borozan I, Xie G, Selzner N, Heathcote EJ, Siminovitch K. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 2012; 142: 1122-1131.e1 [PMID: 22285807]
67. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104 [PMID: 19749758 DOI: 10.1038/ng.447]
68. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]
69. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345, 1345. e1-7 [PMID: 20060832 DOI: 10.1053/j.gastro.2009.12.056]
70. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109 [PMID: 19749757 DOI: 10.1038/ng.449]
71. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509 [PMID: 20434452 DOI: 10.1053/j.gastro.2010.04.049]
72. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI:10.1038/nature08463]
73. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-1896 [PMID: 20931559 DOI:10.1002/hep.23912]
74. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, Soejima Y, Shirabe K, Matsuura Y, Maehara Y. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585, 1585.e1-3 [PMID: 20708617 DOI: 10.1053/j.gastro.2010.07.058]
75. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, Nattermann J, Oldenburg J, Sauerbruch T, Spengler U. Interferon-lambda serum levels in hepatitis C. J Hepatol 2011; 54: 859-865 [PMID: 21145813 DOI: 10.1016/ j.jhep.2010.08.020]
76. Raglow Z, Thoma-Perry C, Gilroy R, Wan YJ. IL28B genotype and the expression of ISGs in normal liver. Liver Int 2013; 33: 991-998 [PMID: 23522062 DOI: 10.1111/liv.12148]
77. Dring MM, Morrison MH, McSharry BP, Guinan KJ, Hagan R, O'Farrelly C, Gardiner CM. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci USA 2011; 108: 5736-5741 [PMID: 21402922 DOI: 10.1073/pnas.1016358108]
78. Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 2012; 56: 444-454 [PMID: 22331604 DOI: 10.1002/hep.25647]
79. Krämer B, Eisenhardt M, Glässner A, Körner C, Sauerbruch T, Spengler U, Nattermann J. Do lambda-IFNs IL28A and IL28B act on human natural killer cells? Proc Natl Acad Sci USA 2011; 108: E519-E520; author reply E521-E322 [PMID: 21825163 DOI: 10.1073/pnas.1108850108]
80. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, Duong FH, Gerlach T, Malinverni R, Moradpour D, Negro F, Müllhaupt B, Bochud PY. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109-1116 [PMID: 23712427 DOI: 10.1084/jem.20130012]
81. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164-171 [PMID: 23291588 DOI: 10.1038/ng.2521]
82. Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in the human liver. Immunol Rev 2000; 174: 5-20 [PMID:10807503DOI:10.1034/j.1600-0528.2002.017416.x]
83. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004; 23: 255-259 [PMID: 14685277 DOI: 10.1038/sj.emboj.7600019]
84. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol 2013; 31: 163-194 [PMID:23298212DOI:0.1146/annurev-immunol-032712-100001]
85. Jinushi M, Takehara T, Tatsumi T, Kanto T, Miyagi T, Suzuki T, Kanazawa Y, Hiramatsu N, Hayashi N. Negative regulation of NK cell activities by inhibitory receptor CD94/ NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 2004; 173: 6072-6081 [PMID: 15528343]
86. Nattermann J, Nischalke HD, Hofmeister V, Ahlenstiel G, Zimmermann H, Leifeld L, Weiss EH, Sauerbruch T, Spengler U. The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol 2005; 166: 443-453 [PMID: 15681828 DOI: 10.1016/S0002-9440(10)62267-5]
87. Grégoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, Walzer T. The trafficking of natural killer cells. Immunol Rev 2007; 220: 169-182 [PMID:17979846DOI:10.1111/j.1600-065X.2007.00563.x]
88. Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, Ahmed P, Missale G, Ferrari C, Khakoo SI. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 2010; 138: 1536-1545 [PMID: 20080094 DOI:10.1053/j.gastro.2010.01.006]
89. Pelletier S, Drouin C, Bédard N, Khakoo SI, Bruneau J, Shoukry NH. Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virusspecific T cell responses. J Hepatol 2010; 53: 805-816 [PMID: 20688412 DOI: 10.1016/j.jhep.2010.05.013]
90. Mondelli MU, Varchetta S, Oliviero B. Natural killer cells in viral hepatitis: facts and controversies. Eur J Clin Invest 2010; 40: 851-863 [PMID: 20597961 DOI:10.1111/j.1365-2362.2010.02332.x]
91. Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford JM, Nelson DR, Liu C. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 2007; 133: 1649-1659 [PMID: 17983809 DOI: 10.1053/j.gastro.2007.09.017]
92. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91 [PMID: 11244031 DOI: 1146/annurev.immunol.19.1.65]
93. Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology 2010; 52: 1581-1589 [PMID: 20812318 DOI: 10.1002/hep.23896]
94. Werner JM, Heller T, Gordon AM, Sheets A, Sherker AH, Kessler E, Bean KS, Stevens M, Schmitt J, Rehermann B. Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection. Hepatology 2013; Epub ahead of print [PMID: 23463364 DOI: 10.1002/ hep.26353]
95. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM, Alexander GJ, Cramp ME, O'Brien SJ, Rosenberg WM, Thomas DL, Carrington M. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872-874 [PMID: 15297676 DOI: 10.1126/ science.1097670]
96. Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Hellard M, Riordan S, Matthews G, Sheridan D, Nattermann J, Smedile A, Müller T, Hammond E, Dunn D, Negro F, Bochud PY, Mallal S, Ahlenstiel G, Stewart GJ, George J, Booth DR. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sec-tional study. PLoS Med 2011; 8: e1001092 [PMID: 21931540 DOI: 10.1371/journal.pmed.1001092]
97. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008; 180: 3969-3979 [PMID: 18322206]
98. Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, Holz LE, Titerence RH, Liang TJ, Rehermann B. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011; 141: 1231-1239, 1239.e1-2 [PMID: 21741920]
99. Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, Stoltzfus J, Noureddin M, Serti E, Feld JJ, Liang TJ, Rotman Y, Rehermann B. Early changes in interferon signaling define natural killer cell response and refractoriness to interferonbased therapy of hepatitis C patients. Hepatology 2012; 55: 39-48 [PMID: 21898483 DOI: 10.1002/hep.24628]
100. Ahlenstiel G, Titerence RH, Koh C, Edlich B, Feld JJ, Rotman Y, Ghany MG, Hoofnagle JH, Liang TJ, Heller T, Rehermann B. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010; 138: 325-335.e1-2 [PMID: 19747917]
101. Miyagi T, Takehara T, Nishio K, Shimizu S, Kohga K, Li W, Tatsumi T, Hiramatsu N, Kanto T, Hayashi N. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection. J Hepatol 2010; 53: 424-430 [PMID: 20554341 DOI: 10.1016/j.jhep.2010.03.018]
102. Bozzano F, Picciotto A, Costa P, Marras F, Fazio V, Hirsch I, Olive D, Moretta L, De Maria A. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur J Immunol 2011; 41: 2905-2914 [PMID: 21695691 DOI: 10.1002/eji.201041361]
103. Oliviero B, Mele D, Degasperi E, Aghemo A, Cremonesi E, Rumi MG, Tinelli C, Varchetta S, Mantovani S, Colombo M, Mondelli MU. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J Hepatol 2013; 59: 38-44 [PMID: 23499727 DOI: 10.1016/j.jhep.2013.03.003]
104. De Maria A, Fogli M, Mazza S, Basso M, Picciotto A, Costa P, Congia S, Mingari MC, Moretta L. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 2007; 37: 445-455 [PMID: 17273991 DOI:10.1002/eji.200635989]
105. Nattermann J, Feldmann G, Ahlenstiel G, Langhans B, Sauerbruch T, Spengler U. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 2006; 55: 869-877 [PMID: 16322112 DOI:10.1136/gut.2005.076463]
106. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D, De Filippi F, Bruno S, Mondelli MU. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009; 137: 1151-1160, 1160.e1-7 [PMID: 19470388]
107. Varchetta S, Mele D, Mantovani S, Oliviero B, Cremonesi E, Ludovisi S, Michelone G, Alessiani M, Rosati R, Montorsi M, Mondelli MU. Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology 2012; 56: 841-849 [PMID: 22431186 DOI: 10.1002/ hep.25723]
108. Crotta S, Brazzoli M, Piccioli D, Valiante NM, Wack A. Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J Hepatol 2010; 52: 183-190 [PMID: 20015567 DOI: 10.1016/ j.jhep.2009.11.003]
109. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F, Abrignani S, Valiante NM. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002; 195: 35-41 [PMID: 11781363 DOI:10.1084/jem.20011124]
110. Krämer B, Schulte D, Körner C, Zwank C, Hartmann A, Michalk M, Söhne J, Langhans B, Nischalke HD, Coenen M, Möhl C, Vogt A, Hennenberg M, Sauerbruch T, Spengler U, Nattermann J. Regulation of NK cell trafficking by CD81. Eur J Immunol 2009; 39: 3447-3458 [PMID: 19830727 DOI:10.1002/eji.200939234]
111. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002; 195: 43-49 [PMID: 11781364 DOI: 10.1084/jem.20011145]
112. Yoon JC, Shiina M, Ahlenstiel G, Rehermann B. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology 2009; 49: 12-21 [PMID: 19085909 DOI: 10.1002/hep.22624]
113. Golden-Mason L, Stone AE, Bambha KM, Cheng L, Rosen HR. Raceand gender-related variation in natural killer p46 expression associated with differential anti-hepatitis C virus immunity. Hepatology 2012; 56: 1214-1222 [PMID: 22505144 DOI: 10.1002/hep.25771]
114. Krämer B, Körner C, Kebschull M, Glässner A, Eisenhardt M, Nischalke HD, Alexander M, Sauerbruch T, Spengler U, Nattermann J. Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology 2012; 56: 1201-1213 [PMID: 22532190 DOI: 10.1002/hep.25804]
115. Pembroke T, Christian A, Jones E, Hills RK, Wang EC, Gallimore AM, Godkin A. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in vivo resistance to interferon α treatment. Gut 2013; Epub ahead of print [PMID: 23665989 DOI: 10.1136/ gutjnl-2013-304472]
116. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88:125-172 [PMID: 18195085 DOI: 10.1152/physrev.00013.2007]
117. Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, Horani A, Nassar M, Friedman SL, Safadi R. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006; 45: 60-71 [PMID: 16515819 DOI: 10.1016/j.jhep.2005.12.025]
118. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006; 130: 435-452 [PMID: 16472598 DOI: 10.1053/j.gastro.2005.10.055]
119. Glässner A, Eisenhardt M, Krämer B, Körner C, Coenen M, Sauerbruch T, Spengler U, Nattermann J. NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasLand NKG2D-dependent manner. Lab Invest 2012; 92: 967-977 [PMID: 22449797 DOI: 10.1038/labinvest.2012.54]
120. Eisenhardt M, Glässner A, Krämer B, Körner C, Sibbing B, Kokordelis P, Nischalke HD, Sauerbruch T, Spengler U, Nattermann J. The CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows dys-regulated activity in hepatitis C. PLoS One 2012; 7: e38846 [PMID: 22792160 DOI: 10.1371/journal. pone.0038846]
121. + T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. J Hepatol 2013; 59: 427-433 [PMID: 23665286 DOI: 10.1016/ j.jhep.2013.04.029]
122. Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007; 104: 6025-6030 [PMID: 17392433 DOI: 10.1073/ pnas.0607026104]
123. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, Feinstone SM, Alter H, Rice CM, McKeating JA. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 2004; 101: 10149-10154 [PMID: 15220475 DOI: 10.1073/pnas.0403519101]
124. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, McKeating JA. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007; 132: 667-678 [PMID: 17258731 DOI: 10.1053/j.gastro.2006.12.008]
125. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008; 14: 25-27 [PMID: 18064037 DOI:10.1038/nm1698]
126. Meunier JC, Russell RS, Goossens V, Priem S, Walter H, Depla E, Union A, Faulk KN, Bukh J, Emerson SU, Purcell RH. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol 2008; 82: 966-973 [PMID: 17977972 DOI: 10.1128/JVI.01872-07]
127. Perotti M, Mancini N, Diotti RA, Tarr AW, Ball JK, Owsianka A, Adair R, Patel AH, Clementi M, Burioni R. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol 2008; 82: 1047-1052 [PMID: 17989176 DOI:10.1128/JVI.01986-07]
128. Semmo N, Lucas M, Krashias G, Lauer G, Chapel H, Klenerman P. Maintenance of HCV-specific T-cell responsesin antibody-deficient patients a decade after early therapy. Blood 2006; 107: 4570-4571 [PMID: 16717132 DOI: 10.1182/ blood-2005-11-4522]
129. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-582 [PMID: 10802716 DOI:10.1038/75063]
130. Abdelwahab SF, Zakaria Z, Sobhy M, Rewisha E, Mahmoud MA, Amer MA, Del Sorbo M, Capone S, Nicosia A, Folgori A, Hashem M, El-Kamary SS. Hepatitis C virusmultispecific T-cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection. Clin Vaccine Immunol 2012; 19: 780-786 [PMID: 22441392 DOI: 10.1128/CVI.00050-12]
131. Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, Haber PS, Marinos G, Levy MH, Kaldor JM, Dolan KA, Ffrench RA, Lloyd AR, Rawlinson WD. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004; 189: 1846-1855 [PMID: 15122521 DOI: 10.1086/383279]
132. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436: 946-952 [PMID: 16107834 DOI: 10.1038/nature04079]
133. Dazert E, Neumann-Haefelin C, Bressanelli S, Fitzmaurice K, Kort J, Timm J, McKiernan S, Kelleher D, Gruener N, Tavis JE, Rosen HR, Shaw J, Bowness P, Blum HE, Klenerman P, Bartenschlager R, Thimme R. Loss of viral fitness and crossrecognition by CD8 T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest 2009; 119: 376-386 [PMID: 19139562]
134. Fitzmaurice K, Petrovic D, Ramamurthy N, Simmons R, Merani S, Gaudieri S, Sims S, Dempsey E, Freitas E, Lea S, McKiernan S, Norris S, Long A, Kelleher D, Klenerman P. Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection. Gut 2011; 60: 1563-1571 [PMID: 21551190 DOI: 10.1136/gut.2010.228403]
135. Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, Berical AC, Feller AJ, Johnson KL, Schulze zur Wiesch J, Robbins GK, Chung RT, Walker BD, Carrington M, Allen TM, Lauer GM. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 2011; 140: 686-696.e1 [PMID: 20875418]
136. Neumann-Haefelin C, Thimme R. Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection. Genes Immun 2007; 8: 181-192 [PMID: 17230195 DOI: 10.1038/sj.gene.6364368]
137. + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197: 1645-1655 [PMID: 12810686 DOI:10.1084/jem.20030239]
138. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659-662 [PMID: 14576438 DOI:10.1126/science.1088774]
139. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499-1512 [PMID: 10790425 DOI: 10.1084/jem.191.9.1499]
140. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-1406 [PMID: 11714747 DOI: 10.1084/jem.194.10.1395]
141. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, Eichenlaub D, Pape GR. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-1007 [PMID: 7475549 DOI:10.1016/S0140-6736(95)91691-1]
142. Hiroishi K, Kita H, Kojima M, Okamoto H, Moriyama T, Kaneko T, Ishikawa T, Ohnishi S, Aikawa T, Tanaka N, Yazaki Y, Mitamura K, Imawari M. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. Hepatology 1997; 25: 705-712 [PMID: 9049223 DOI: 10.1002/ hep.510250336]
143. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M, Lau JY. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997; 158: 1473-1481 [PMID: 9013994]
144. Rehermann B, Chang KM, McHutchinson J, Kokka R, Houghton M, Rice CM, Chisari FV. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996; 70: 7092-7102 [PMID: 8794355]
145. Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis 1997; 176: 859-866 [PMID: 9333142 DOI: 10.1086/516546]
146. + T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005; 42: 104-112 [PMID: 15962289 DOI: 10.1002/ hep.20749]
147. Folgori A, Spada E, Pezzanera M, Ruggeri L, Mele A, Garbuglia AR, Perrone MP, Del Porto P, Piccolella E, Cortese R, Nicosia A, Vitelli A. Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut 2006; 55: 1012-1019 [PMID:16484505 DOI: 10.1136/gut.2005.080077]
148. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, Hoffmann R, Schirren CA, Santantonio T, Pape GR. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933-941 [PMID: 10500077 DOI:10.1016/S0016-5085(99)70353-7]
149. + T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 2000; 30: 2479-2487 [PMID: 11009080]
150. Grabowska AM, Lechner F, Klenerman P, Tighe PJ, Ryder S, Ball JK, Thomson BJ, Irving WL, Robins RA. Direct exvivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol 2001; 31: 2388-2394 [PMID: 11500822]
151. He XS, Rehermann B, López-Labrador FX, Boisvert J, Cheung R, Mumm J, Wedemeyer H, Berenguer M, Wright TL, Davis MM, Greenberg HB. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999; 96: 5692-5697 [PMID: 10318946 DOI: 10.1073/ pnas.96.10.5692]
152. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, Ferrari C. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 2007; 45: 588-601 [PMID: 17326153 DOI: 10.1002/hep.21541]
153. + T cells in chronic hepatitis C virus infection. J Immunol 2002; 169: 3447-3458 [PMID: 12218168]
154. + T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010; 6: e1000947 [PMID: 20548953 DOI: 10.1371/ journal.ppat.1000947]
155. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10: 29-37 [PMID: 19043418 DOI: 10.1038/ni.1679]
156. McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M, Allen TM, Gretch DR, Rosen HR. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 2010; 120: 4546-4557 [PMID: 21084749 DOI: 10.1172/JCI43127]
157. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M, Gostick E, Price DA, Freeman GJ, Wherry EJ, Chang KM. Synergistic reversal of intrahepatic HCVspecific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 2009; 5: e1000313 [PMID: 19247441 DOI: 10.1371/journal.ppat.1000313]
158. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, Hanson HL, Steinberg JP, Masopust D, Wherry EJ, Altman JD, Rouse BT, Freeman GJ, Ahmed R, Grakoui A. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007; 81: 2545-2553 [PMID: 17182670 DOI:10.1128/JVI.02021-06]
159. + T cells. PLoS Pathog 2011; 7: e1002045 [PMID: 21625589 DOI: 10.1371/journal.ppat.1002045]
160. Nakamoto N, Kaplan DE, Coleclough J, Li Y, Valiga ME, Kaminski M, Shaked A, Olthoff K, Gostick E, Price DA, Freeman GJ, Wherry EJ, Chang KM. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 2008; 134: 1927-1937, 1937.e1-2 [PMID: 18549878]
161. Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, Sidney J, Sette A, Pardoll D, Thomas DL, Ray SC. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 2005; 201: 1741-1752 [PMID: 15939790 DOI:10.1084/jem.20050121]
162. Ray SC, Fanning L, Wang XH, Netski DM, Kenny-Walsh E, Thomas DL. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med 2005; 201: 1753-1759 [PMID: 15939791 DOI: 10.1084/ jem.20050122]
163. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, Pillay T, Ouchi K, Reyor LL, Schulze zur Wiesch J, Gandhi RT, Chung RT, Bhardwaj N, Klenerman P, Walker BD, Allen TM. CD8 epitope escape and reversion in acute HCV infection. J Exp Med 2004; 200: 1593-1604 [PMID: 15611288 DOI: 10.1084/jem.20041006]
164. T cells in early viral evolution. J Virol 2011; 85: 11833-11845 [PMID: 21900166 DOI: 10.1128/ JVI.02654-10]
165. Meyer-Olson D, Shoukry NH, Brady KW, Kim H, Olson DP, Hartman K, Shintani AK, Walker CM, Kalams SA. Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp Med 2004; 200: 307-319 [PMID: 15289502 DOI: 10.1084/jem.20040638]
166. Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, Dowd KA, Clute S, Wang C, Korman A, Sette A, Sidney J, Pardoll DM, Cox AL. High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol 2008; 181: 8215-8225 [PMID: 19050238]
167. + T cells. Eur J Immunol 1993; 23: 3306-3311 [PMID: 8258345 DOI: 10.1002/ eji.1830231237]
168. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492-499 [PMID: 21739672 DOI: 10.1038/ni.2035]
169. Larrubia JR, Lokhande MU, García-Garzón S, Miquel J, González-Praetorius A, Parra-Cid T, Sanz-de-Villalobos E. Persistent hepatitis C virus (HCV) infection impairs HCV specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation. J Viral Hepat 2013; 20: 85-94 [PMID: 23301543 DOI:0.1111/j.1365-2893.2012.01618.x]
170. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, Abrignani S, Mondelli MU, Barnaba V. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest 2004; 113: 963-972 [PMID: 15057302]
171. + T cells during acute hepatitis C. Gastroenterology 2009; 137: 1280-8.e1-6 [PMID: 19596013]
172. Langhans B, Braunschweiger I, Arndt S, Schulte W, Satoguina J, Layland LE, Vidovic N, Hoerauf A, Oldenburg J, Sauerbruch T, Spengler U. Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. Clin Sci (Lond) 2010; 119: 97-109 [PMID: 20222873 DOI: 10.1042/CS20090661]
173. + T cells during chronic hepatitis C virus infection. J Virol 2005; 79: 7860-7867 [PMID: 15919940DOI:10.1128/JVI.79.12.7860-7867.2005]
174. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, Nelson DR. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40: 1062-1071 [PMID: 15486925 DOI: 10.1002/hep.20454]
175. + T cells during persistent hepatitis C virus infection. J Virol 2005; 79: 7852-7859 [PMID: 15919939 DOI:10.1128/JVI.79.12.7852-7859.2005]
176. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003; 38: 1437-1448 [PMID: 14647055]
177. + regulatory T cells and fibrogenesis in chronic hepatitis C. J Hepatol 2013; 59: 229-235 [PMID: 23624000 DOI: 10.1016/j.jhep.2013.04.011]
178. Mahmood S, Sho M, Yasuhara Y, Kawanaka M, Niiyama G, Togawa K, Ito T, Takahashi N, Kinoshita M, Yamada G. Clinical significance of intrahepatic interleukin-8 in chronic hepatitis C patients. Hepatol Res 2002; 24: 413-419 [PMID: 12479940 DOI: 10.1016/S1386-6346(02)00136-5]
179. Asselah T, Bièche I, Laurendeau I, Paradis V, Vidaud D, Degott C, Martinot M, Bedossa P, Valla D, Vidaud M, Marcellin P. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005; 129: 2064-2075[PMID: 16344072 DOI: 10.1053/j.gastro.2005.09.010]
180. Claassen MA, de Knegt RJ, Tilanus HW, Janssen HL, Boonstra A. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol 2010; 52: 315-321 [PMID: 20129690 DOI: 10.1016/j.jhep.2009.12.013]
181. Sturm N, Thélu MA, Camous X, Dimitrov G, Ramzan M, Dufeu-Duchesne T, Bonorino P, Guillermet C, Brambilla E, Arvers P, Pernollet M, Leroy V, Zarski JP, Marche PN, Jouvin Marche E. Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis. J Hepatol 2010; 53: 25-35 [PMID: 20452085 DOI: 10.1016/j.jhep.2010.02.024]
182. Ward SM, Fox BC, Brown PJ, Worthington J, Fox SB, Chapman RW, Fleming KA, Banham AH, Klenerman P. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol 2007; 47: 316-324 [PMID: 17475362 DOI:10.1016/j.jhep.2007.03.023]
183. Girard S, Shalhoub P, Lescure P, Sabile A, Misek DE, Hanash S, Bréchot C, Beretta L. An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology 2002; 295: 272-283 [PMID: 12033786 DOI:10.1006/viro.2002.1373]
184. Jia Y, Wei L, Jiang D, Wang J, Cong X, Fei R. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8. J Gastroenterol Hepatol 2007; 22: 1278-1285 [PMID: 17565587 DOI:10.1111/j.1440-1746.2007.04957.x]
185. + Th1, Th2, and regulatory T cell clones in hepatitis C. PLoS One 2012; 7: e42094 [PMID: 22848715 DOI: 10.1371/journal.pone.0042094]